Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2014

View Archived Issues

Sichuan Haisco Pharmaceutical synthesizes novel FFAR1 agonists for diabetes

Novel animal models to study human neurological disorders

NetScientific invests in PDS Biotechnology

Taiho describes new androgen receptor antagonist for prostate cancer treatment

Prima BioMed initiates pilot trial of CVac in pancreatic cancer

Preclinical data for RG-7888 support phase I investigation

Capstone Therapeutics reports phase Ib/IIa study results for AEM-28

Novogen's TRXE-009 shows potential in melanoma

Stemline studies SL-401 in four rare myeloproliferative neoplasms

Isis studies ISIS-DMPKRx in new phase I/II trial for myotonic dystrophy type 1

Emergent BioSolutions acquires Evolva antibacterial program

Boston Strategics and MD Anderson sign risk-sharing agreement for study of E-6201

Preclinical results presented for BB-R12, a novel gene therapy for heart failure

Preliminary phase I/IIa data for an anticancer vaccine against multiple myeloma

A*STAR patents novel Wnt pathway modulators

Sumitomo Dainippon Pharma presents new dopamine D4 receptor agonists

Scientists at TransTech Pharma disclose novel Aurora kinase inhibitors

VPAC agonists show promising results as neuroprotectors in Parkinson's disease model

Velocity Pharmaceutical and Tigercat Pharma report phase II results for VPD-737

Yumanity Therapeutics launched to develop new therapies for neurodegenerative diseases

TxCell's Col-Treg receives E.U. orphan drug designation for non-infectious uveitis

Lundbeck discontinues development of desmoteplase

FDA approves ear drop formulation of finafloxacin for acute otitis externa

Poxel reports results from phase IIb trial of imeglimin in type 2 diabetes

Pozen receives second complete response letter from FDA regarding Yosprala

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...